GlassScriptPhysician profile
Edward F Ryan
NPI 1699703934
$159,265.59
in general payments reported to CMS, 2019-2025
27 companies · $945 in 2025
The $945 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $54K · 2021: $2,490 · 2022: $11K · 2023: $37K · 2024: $1,263 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $4,329 · Travel and Lodging: $2,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,650.00 |
| Food and Beverage | $4,328.75 |
| Travel and Lodging | $2,746.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $153,059.10 | 2019-2025 | Aklief, Epsolay, Twyneo |
| Abbvie INC. | $1,048.60 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $1,037.44 | 2019-2025 | Tremfya, Remicade, Stelara |
| Vyne Pharmaceuticals INC. | $439.07 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $381.65 | 2019-2025 | |
| Leo Pharma INC. | $349.99 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $341.18 | 2019-2025 | Otezla |
| Genzyme Corporation | $334.29 | 2021-2025 | |
| Incyte Corporation | $313.90 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $298.72 | 2020-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $297.20 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Dermavant Sciences, INC. | $287.22 | 2023-2024 | Vtama |
| Ucb, INC. | $254.22 | 2022-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $152.02 | 2023-2025 | Zoryve |
| Pfizer INC. | $150.38 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $104.32 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $67.29 | 2020-2023 | Olumiant, Taltz |
| Organon LLC | $66.38 | 2024-2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.12 | 2020-2025 | Cabtreo |
| Almirall LLC | $58.59 | 2024-2025 | Klisyri, Seysara |
| Celgene Corporation | $54.49 | 2019 | |
| Dermira, INC. | $32.15 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $24.69 | 2024 | |
| Journey Medical Corporation | $14.67 | 2022 | |
| Epi Health, LLC | $13.37 | 2022 | |
| Promius Pharma LLC | $11.81 | 2019 | |
| Mission Pharmacal Company | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.